These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18027478)

  • 1. Stent sales slide. Hospitals using fewer drug-eluting devices.
    Rhea S
    Mod Healthc; 2007 Oct; 37(42):14-5. PubMed ID: 18027478
    [No Abstract]   [Full Text] [Related]  

  • 2. By the numbers. Suppliers/purchasing.
    Mod Healthc; 2007 Dec; Suppl():70, 72, 74 passim. PubMed ID: 18220137
    [No Abstract]   [Full Text] [Related]  

  • 3. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
    Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
    J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stent prices continue slow downward spiral. Price pressure mounts from adverse clinical findings, new competition.
    Hosp Mater Manage; 2008 Aug; 33(8):5-7. PubMed ID: 18754540
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation.
    Zhang RY; DU R; Zhu ZB; Zhang Q; Hu J; Lü AK; Zhang JS; Shen WF
    Chin Med J (Engl); 2008 Dec; 121(24):2504-8. PubMed ID: 19187586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stent data show shift in physician preferences.
    Hosp Mater Manage; 2007 Sep; 32(9):8-9. PubMed ID: 17896550
    [No Abstract]   [Full Text] [Related]  

  • 7. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent.
    Zhang F; Qian J; Ge J
    J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Roy P; Buch AN; Javaid A; Okabe T; Raya V; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Feb; 101(3):293-9. PubMed ID: 18237587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drug-eluting stent (DES) market.
    Waksman R
    Cardiovasc Revasc Med; 2008; 9(3):131. PubMed ID: 18606374
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on drug-eluting stents.
    Sims JM
    Dimens Crit Care Nurs; 2007; 26(6):237-40. PubMed ID: 18090139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials.
    Sanchez-Recalde A; Moreno R; Barreales L; Rivero F; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
    J Invasive Cardiol; 2008 Aug; 20(8):417-22. PubMed ID: 18688067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparity in drug-eluting stent utilization by insurance type.
    Kao J; Vicuna R; House JA; Rumsfeld JS; Ting HH; Spertus JA
    Am Heart J; 2008 Dec; 156(6):1133-40. PubMed ID: 19033009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting stent fracture and acute coronary syndrome.
    Chhatriwalla AK; Cam A; Unzek S; Bhatt DL; Raymond RE; Lincoff AM; Whitlow PL; Ellis SG; Tuzcu EM; Kapadia SR
    Cardiovasc Revasc Med; 2009; 10(3):166-71. PubMed ID: 19595398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
    Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
    Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital-physician gainsharing in cardiology.
    Ketcham JD; Furukawa MF
    Health Aff (Millwood); 2008; 27(3):803-12. PubMed ID: 18474974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dark side of drug-eluting stent: multiple stent fractures and sudden death.
    Kang WY; Kim W; Hwang SH; Kim W
    Int J Cardiol; 2009 Mar; 132(3):e125-7. PubMed ID: 18077021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stent safety: findings from preclinical studies.
    Nakazawa G; Finn AV; Ladich E; Ribichini F; Coleman L; Kolodgie FD; Virmani R
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1379-91. PubMed ID: 19018691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SA experts comment on clopidogrel and aspirin (dual platelet therapy) use with bare metal and drug-eluting stents.
    Cardiovasc J Afr; 2008; 19(1):58. PubMed ID: 18320095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.